Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HPA Clear all
Completed No phase listed Observational

Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults

NCT01900275
View directory record Official record
Conditions
Sepsis, Trauma, Shock, Acute Kidney Injury
Interventions
Urine collection
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study - Impact of Traditional Acupuncture on Menopause

NCT00950482
View directory record Official record
Conditions
Menopause
Interventions
TA, AA, WC
Procedure · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

NCT01137032
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
Pandel Cream 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
3 Months and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 21, 2026, 1:28 PM EDT
Approved For Marketing No phase listed Expanded access

Sapropterin Expanded Access Program

NCT00484991
View directory record Official record
Conditions
Phenylketonuria
Interventions
Sapropterin dihydrochloride
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
9 Years and older
U.S. locations
36
States / cities
Los Angeles, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2008 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 2 Interventional Results available

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02131324
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06 Cream, Clobetasol Propionate Cream 0.05%
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Glendale, Arizona • Mesa, Arizona • Encino, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 21, 2026, 1:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression

NCT00001479
View directory record Official record
Conditions
Fatigue Syndrome, Chronic, Healthy, Mood Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 1:28 PM EDT
Recruiting Phase 4 Interventional

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

NCT07477691
View directory record Official record
Conditions
Phenylketonuria
Interventions
Pegvaliase, Methotrexate
Biological · Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis

NCT01282164
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
Interventions
glucagon stimulation test and insulin tolerance test
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Cleveland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 21, 2026, 1:28 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis

NCT06317688
View directory record Official record
Conditions
Lactation Mastitis, Breast Feeding, Staphylococcus Aureus Infection
Interventions
Extra-Virgin Coconut Oil
Dietary Supplement
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 1 Interventional

Dutasteride to Treat Women With Menstrually Related Mood Disorders

NCT00082043
View directory record Official record
Conditions
Premenstrual Syndrome, PMS, Healthy, Depression
Interventions
Dutasteride, Placebo oral capsule
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
30 Years to 50 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

NCT01133626
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Placebo Nasal Aerosol, Prednisone capsules, Placebo Prednisone Capsules, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
North Dartmouth, Massachusetts • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2012 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01086410
View directory record Official record
Conditions
Asthma
Interventions
Placebo Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Placebo Oral Capsule, Prednisolone Oral Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Cypress, California • Huntington Beach, California • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 2 Interventional Results available

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

NCT01043393
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone 0.25% spray
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Hot Springs, Arkansas • Albuquerque, New Mexico • Simpsonville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)

NCT00065299
View directory record Official record
Conditions
Phenylketonuria
Interventions
Restricted phenylalanine diet
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
0 Years and older · Female only
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1984 – 2000
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 1:28 PM EDT
Completed No phase listed Observational

Bone Mineral Density in Adults With Hyperphenylalaninemia

NCT01209819
View directory record Official record
Conditions
Phenylketonurias
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

NCT01697956
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
BDP, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Long Beach, California • Stockbridge, Georgia • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 21, 2026, 1:28 PM EDT
Terminated Phase 3 Interventional Results available

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

NCT02527421
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DFD01 Spray
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
12 Years to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Encino, California • Irvine, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Not applicable Interventional

The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation

NCT00688987
View directory record Official record
Conditions
Obesity, Addison's Disease
Interventions
Hydrocortisone, Isocaloric Diet
Drug · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Oct 21, 2026, 1:28 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Detection of miRNAs in HPA Axis Function in Healthy Subjects

NCT04066647
View directory record Official record
Conditions
Dexamethasone Effect on miRNA Profile in Healthy Humans
Interventions
Dexamethasone 4mg
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 21, 2026, 1:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

NCT03847389
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Clobetasol propionate 0.05% Topical Oil
Drug
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Sanford, Florida • Savannah, Georgia • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency

NCT00355264
View directory record Official record
Conditions
Tetrahydrobiopterin Deficiencies, Hyperphenylalaninemia, Non-Phenylketonuric
Interventions
Phenoptin
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 21, 2026, 1:28 PM EDT
Completed No phase listed Observational

PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry

NCT00778206
View directory record Official record
Conditions
Phenylketonuria, Hyperphenylalaninaemia
Interventions
Kuvan
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
1,887 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
45
States / cities
Los Angeles, California • Orange, California • San Diego, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 21, 2026, 1:28 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
View directory record Official record
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 21, 2026, 1:28 PM EDT